October 25, 2014 6:27 PM ET


Company Overview of Fumapharm AG

Company Overview

As of May 31, 2006, Fumapharm AG was acquired by Biogen Idec, Inc. Fumapharm AG, a pharmaceutical company, develops therapeutics. Its products include FUMADERM for the treatment of psoriasis; and BG-12 for the treatment of multiple sclerosis and psoriasis. The company was founded in 1983 and is headquartered in Luzern, Switzerland.

Tribschenstrasse 7

Luzern,  6002


Founded in 1983


41 41 371 20 46


41 41 371 20 48

Key Executives for Fumapharm AG

Fumapharm AG does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Novartis Vaccines and Diagnostics Services AG Europe
Pfizer A.G. Europe
TopoTarget Switzerland S.A. Europe
Pelletech Ltd. Europe
F. Hoffmann-La Roche Ltd Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Fumapharm AG, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.